Dechra Pharmaceuticals plc (LON:DPH)‘s stock had its “under review” rating restated by research analysts at FinnCap in a research report issued on Tuesday.

A number of other equities analysts also recently commented on the company. Numis Securities Ltd reissued an “add” rating and set a GBX 1,520 ($18.86) price objective on shares of Dechra Pharmaceuticals plc in a research report on Thursday, October 27th. N+1 Singer boosted their price objective on Dechra Pharmaceuticals plc from GBX 1,350 ($16.75) to GBX 1,412 ($17.52) and gave the stock a “buy” rating in a research report on Friday, October 21st. Stifel Nicolaus reaffirmed a “hold” rating and issued a GBX 1,250 ($15.51) price target on shares of Dechra Pharmaceuticals plc in a report on Friday, October 21st. Panmure Gordon reaffirmed a “buy” rating and issued a GBX 1,140 ($14.14) price target on shares of Dechra Pharmaceuticals plc in a report on Sunday, September 11th. Finally, Jefferies Group upped their price target on Dechra Pharmaceuticals plc from GBX 1,229 ($15.25) to GBX 1,295 ($16.07) and gave the company a ” hold” rating in a report on Wednesday, September 7th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of GBX 1,333.86 ($16.55).

Analyst Recommendations for Dechra Pharmaceuticals plc (LON:DPH)

Dechra Pharmaceuticals plc (LON:DPH) opened at 1275.00 on Tuesday. Dechra Pharmaceuticals plc has a 52-week low of GBX 811.00 and a 52-week high of GBX 1,462.00. The stock’s market capitalization is GBX 1.18 billion. The firm’s 50-day moving average is GBX 1,326.89 and its 200-day moving average is GBX 1,267.41.

The company also recently disclosed a dividend, which was paid on Friday, November 18th. Shareholders of record on Thursday, October 27th were paid a GBX 12.91 ($0.16) dividend. The ex-dividend date was Thursday, October 27th. This represents a yield of 0.92%. This is a boost from Dechra Pharmaceuticals plc’s previous dividend of $5.55.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Financial Market News and is the propert of of Financial Market News. If you are reading this piece on another publication, it was stolen and reposted in violation of US and international trademark and copyright law. The original version of this piece can be viewed at http://www.financial-market-news.com/finncap-reiterates-under-review-rating-for-dechra-pharmaceuticals-plc-dph/1208410/.

About Dechra Pharmaceuticals plc

Dechra Pharmaceuticals PLC is a veterinary pharmaceuticals company. The Company is engaged in the development, manufacture and marketing of products for veterinarians across the world. The Company’s segments include European Pharmaceuticals, consists of Dechra Veterinary Products EU and Dechra Pharmaceuticals Manufacturing; North American (NA) Pharmaceuticals, consists of Dechra Veterinary Products US and Dechra Veterinary Products Canada, and Pharmaceuticals Research and Development.

Receive News & Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related companies with MarketBeat.com's FREE daily email newsletter.